{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:30:54Z","timestamp":1791307854172,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81273375"],"award-info":[{"award-number":["81273375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jphs.2015.03.010","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T19:59:10Z","timestamp":1428263950000},"page":"462-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb\/IIIa"],"prefix":"10.1016","volume":"127","author":[{"given":"Yi","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2015.03.010_bib1","first-page":"528","article-title":"Prevention of cardiovascular diseases in developing countries","volume":"15","author":"Total","year":"2012","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.jphs.2015.03.010_bib2","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1161\/01.CIR.0000133427.35111.67","article-title":"Principles for national and regional guidelines on cardiovascular disease prevention a scientific statement from the World Heart and Stroke Forum","volume":"109","author":"Smith","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2015.03.010_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198610163151602","article-title":"Platelet activation in unstable coronary disease","volume":"315","author":"Fitzgerald","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2015.03.010_bib4","first-page":"148","article-title":"Platelets in perspective","volume":"134","author":"White","year":"1981","journal-title":"West J Med"},{"key":"10.1016\/j.jphs.2015.03.010_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1474-5151(02)00038-5","article-title":"Platelets and cardiovascular disease","volume":"1","author":"Willoughby","year":"2002","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.jphs.2015.03.010_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jphs.08R06FM","article-title":"Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease","volume":"108","author":"Chintala","year":"2008","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2015.03.010_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V88.3.907.907","article-title":"Analysis of GPIIb\/IIIa receptor number by quantification of 7E3 binding to human platelets","volume":"88","author":"Wagner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2015.03.010_bib8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH11-10-0727","article-title":"GPIIb\/IIIa inhibitors: from bench to bedside and back to bench again","volume":"107","author":"Armstrong","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jphs.2015.03.010_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/00004647-200006000-00011","article-title":"ME3277, a GPIIb\/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery","volume":"20","author":"Kawano","year":"2000","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.jphs.2015.03.010_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ahj.2007.12.034","article-title":"Antiplatelet drug nonresponsiveness","volume":"155","author":"Gladding","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jphs.2015.03.010_bib11","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.thromres.2012.02.047","article-title":"A\u00a0novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb\/IIIa inhibits platelet aggregation","volume":"129","author":"Li","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jphs.2015.03.010_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1254\/jphs.93.381","article-title":"Platelets and anti-platelet therapy","volume":"93","author":"McNicol","year":"2003","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2015.03.010_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002130.pub2","article-title":"Platelet glycoprotein IIb\/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes","volume":"9","author":"Bosch","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jphs.2015.03.010_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2015.03.010_bib15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI36745","article-title":"Eptifibatide-induced thrombocytopenia and thrombosis in humans require Fc\u03b3RIIa and the integrin \u03b23 cytoplasmic domain","volume":"119","author":"Gao","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2015.03.010_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11239-006-8669-4","article-title":"Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb\/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes-(OPUS-TIMI 16) trial","volume":"22","author":"Scirica","year":"2006","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jphs.2015.03.010_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.toxicon.2009.03.027","article-title":"A\u00a0novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization","volume":"54","author":"Kong","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.jphs.2015.03.010_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1254\/jphs.11123FP","article-title":"Chrysophanol-8-O-glucoside, an anthraquinone derivative in rhubarb, has antiplatelet and anticoagulant activities","volume":"118","author":"Seo","year":"2012","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2015.03.010_bib19","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2011-11-392787","article-title":"A\u00a0novel mechanism of sustained platelet \u03b1IIb\u03b23 activation via PEAR1","volume":"119","author":"Kauskot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2015.03.010_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born","year":"1963","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jphs.2015.03.010_bib21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1160\/TH11-01-0029","article-title":"A\u00a0novel family of RGD-containing disintegrin (Tablysin-15) from the salivary gland of the horsefly Tabanus yao targets integrins \u03b1IIb\u03b23 and \u03b1V\u03b23 and inhibits platelet aggregation and angiogenesis","volume":"105","author":"Ma","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jphs.2015.03.010_bib22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2007.02717.x","article-title":"Evaluation of aprotinin and tranexamic acid in different in\u00a0vitro and in\u00a0vivo models of fibrinolysis, coagulation and thrombus formation","volume":"5","author":"Sperzel","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jphs.2015.03.010_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0038-1657230","article-title":"Bleeding time in rats: a comparison of different experimental conditions","volume":"48","author":"Dejana","year":"1982","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jphs.2015.03.010_bib24","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.2174\/138161210794519255","article-title":"Targeting the platelet integrin GPIIb\/IIIa","volume":"16","author":"Hagemeyer","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jphs.2015.03.010_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCRESAHA.112.300570","article-title":"Integrin \u03b1IIb\u03b23 from discovery to efficacious therapeutic target","volume":"112","author":"Bledzka","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2015.03.010_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2015.03.010_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/01.CIR.102.10.1093","article-title":"Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb\/IIIa inhibition insights from the platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial","volume":"102","author":"Lincoff","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2015.03.010_bib28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jcin.2010.09.015","article-title":"The evolving role of glycoprotein IIb\/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes","volume":"3","author":"Hanna","year":"2010","journal-title":"JACC: Cardiovasc Interv"},{"key":"10.1016\/j.jphs.2015.03.010_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003576","article-title":"Structure-guided design of a high-affinity platelet integrin \u03b1IIb\u03b23 receptor antagonist that disrupts Mg2+ binding to the MIDAS","volume":"4","author":"Zhu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jphs.2015.03.010_bib30","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1096\/fj.04-1513fje","article-title":"Single-chain antibodies for the conformation-specific blockade of activated platelet integrin \u03b1IIb\u03b23 designed by subtractive selection from naive human phage libraries","volume":"18","author":"Schwarz","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.jphs.2015.03.010_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa a novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2015.03.010_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1160\/TH07-10-0645","article-title":"Allosteric regulation of \u03b1IIb\u03b23 by \u03b23 95\u2013105","volume":"99","author":"Haas","year":"2008","journal-title":"Thromb Haemost"},{"issue":"7474","key":"10.1016\/j.jphs.2015.03.010_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A\u00a0directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T13:31:36Z","timestamp":1598880696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861315000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1347861315000729"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2015.03.010","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb\/IIIa","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2015.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}